title: A study of prevention and regression of cardiac hypertrophy with a prolactin inhibitor in a biological model of ventricular hypertrophy caused by aorto caval fistulae in rat.
abstract: BACKGROUND
  The possibility of decreasing or reverting left ventricular hypertrophy and, therefore, cardiac hypertrophy (CH) is an important medical issue. The aim of the present study was to evaluate these two possibilities with a 3-week daily dose of captopril, losartan, or bromocriptine in a preventive or corrective model.
  
  
  METHODS
  After aorto caval fistulae (ACF) surgery on adult male Wistar rats to induce CH, animals were assigned to the preventive protocol (drug treatment began immediately after surgery) or corrective protocol (hypertrophy was allowed to develop before drug treatment). After treatments, isoproterenol was administered to half of the animals to further induce CH. The groups included the passive control, the sham-operated animals, those with ACF surgery but without drug treatment, and the 3-week treatments with captopril, losartan, or the low or high dose of bromocriptine.
  
  
  RESULTS
  Three treatments, with captopril, losartan, or the high dose of bromocriptine, significantly impeded/reverted an increase in CH-related parameters in the preventive/corrective model compared to the surgically treated group without drug treatment. The same effect was found after isoproterenol administration. The present results show an avoidance/reversion of CH with these three treatments. Better results were found with the angiotensin converting enzyme inhibitor (captopril) than with the prolactin inhibitor (bromocriptine).
  
  
  CONCLUSIONS
  Treatments with captopril, losartan, and the high dose of bromocriptine were effective in preventing/reversing the manifestation of CH in the preventive/corrective rat models. Further studies are needed to identify the initial mediator, the key component, and the molecular events involved in the pathogenesis of CH.
authors.affiliation: Intracellular Signaling Laboratory, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, México.
authors.forename: Juan M
authors.initials: JM
authors.lastname: Vélez
authors.forename: Germán A
authors.initials: GA
authors.lastname: Chamorro
authors.forename: Claudia C
authors.initials: CC
authors.lastname: Calzada
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Zuñiga
authors.forename: Juan J
authors.initials: JJ
authors.lastname: Vélez
authors.forename: Esther
authors.initials: E
authors.lastname: Ocharán
mesh_terms: D000818:Animals; D001018:Aortic Diseases / Q000150:complications; D001164:Arteriovenous Fistula / Q000150:complications; D001794:Blood Pressure / Q000187:drug effects; D001971:Bromocriptine / Q000008:administration & dosage; D002216:Captopril / Q000008:administration & dosage; D006332:Cardiomegaly / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control*; D004195:Disease Models, Animal; D006727:Hormone Antagonists / Q000008:administration & dosage; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control; D019808:Losartan / Q000008:administration & dosage; D008297:Male; D011388:Prolactin / Q000037:antagonists & inhibitors*; D051381:Rats; D017208:Rats, Wistar; D014682:Vena Cava, Inferior
chemical_list: D006727:Hormone Antagonists; D001971:Bromocriptine; D011388:Prolactin; D002216:Captopril; D019808:Losartan
keywords: Aorto caval fistulae; Cardiac hypertrophy; Cardiac remodeling; Heart failure; Left ventricular hypertrophy